Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019

被引:39
作者
Nakamura, Yasuhiro [1 ]
Asai, Jun [2 ]
Igaki, Hiroshi [3 ]
Inozume, Takashi [4 ]
Namikawa, Kcnjiro [5 ]
Hayashi, Ayato [6 ]
Fukushima, Satoshi [7 ]
Fujimura, Taku [8 ]
Ito, Takamichi [9 ]
Imafuku, Keisuke [10 ]
Tanaka, Ryota [11 ]
Teramoto, Yukiko [1 ]
Minagawa, Akane [12 ]
Miyagawa, Takuya [13 ]
Miyashita, Azusa [7 ]
Wada, Makoto [2 ]
Koga, Hiroshi [12 ]
Sugaya, Makoto [14 ]
机构
[1] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, 1397-1 Yamane, Saitama 3501298, Japan
[2] Kyoto Prefectural Univ Med, Dept Dermatol, Kyoto, Japan
[3] Natl Canc Ctr, Dept Radiat Oncol, Tokyo, Japan
[4] Univ Yamanashi, Dept Dermatol, Kofu, Yamanashi, Japan
[5] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan
[6] Juntendo Univ, Dept Plast & Reconstruct Surg, Urayasu Hosp, Urayasu, Japan
[7] Kumamoto Univ, Dept Dermatol Plast & Reconstruct Surg, Kumamoto, Japan
[8] Tohoku Univ, Dept Dermatol, Sendai, Miyagi, Japan
[9] Kyushu Univ, Grad Sch Med Sci, Dept Dermatol, Fukuoka, Fukuoka, Japan
[10] Hokkaido Univ, Dept Dermatol, Sapporo, Hokkaido, Japan
[11] Univ Tsukuba, Fac Med, Dept Dermatol, Tsukuba, Ibaraki, Japan
[12] Shinshu Univ, Dept Dermatol, Matsumoto, Nagano, Japan
[13] Univ Tokyo, Dept Dermatol, Tokyo, Japan
[14] Int Univ Hlth & Welf, Dept Dermatol, Narita, Japan
关键词
cutaneous melanoma; grade system; guidelines; immune checkpoint inhibitor; molecular-targeted agent; LYMPH-NODE DISSECTION; STAGE-III MELANOMA; DABRAFENIB PLUS TRAMETINIB; SUBUNGUAL MELANOMA; ADJUVANT THERAPY; FOLLOW-UP; PEGYLATED INTERFERON-ALPHA-2B; OPEN-LABEL; SURGICAL-MANAGEMENT; MALIGNANT-MELANOMA;
D O I
10.1111/1346-8138.15151
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
With consideration of the ongoing developments in treatment options for cutaneous melanoma, the Japanese Skin Cancer Society published the first guidelines for cutaneous melanoma in 2007 and later revised them in 2015. Here, we report on an English version of the 2019 Japanese Melanoma Guidelines. In this latest edition, all processes were carried out according to the Grading of Recommendations, Assessment, Development and Evaluation system. A comprehensive published work search, systematic review and determination of recommendations in each clinical question were performed by a multidisciplinary expert panel consisting of dermatologists, a plastic and reconstructive surgeon, and a radiation oncologist. The advent of novel agents, such as immune checkpoint inhibitors and molecular-targeted agents, has drastically changed the nature of treatment for adjuvant and advanced-stage diseases among melanoma patients worldwide. Additionally, recent reports of clinical trials regarding surgical procedures and a better understanding of molecular biology and tumor immunology in clinical types of melanoma have had an impact on clinical practise. Based on these viewpoints, eight relevant clinical questions were raised in this report that aim to help clinicians select the appropriate therapeutic approach.
引用
收藏
页码:89 / 103
页数:15
相关论文
共 64 条
[11]  
2-D
[12]   Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial [J].
Davies, Michael A. ;
Saiag, Philippe ;
Robert, Caroline ;
Grob, Jean-Jacques ;
Flaherty, Keith T. ;
Arance, Ana ;
Chiarion-Sileni, Vanna ;
Thomas, Luc ;
Lesimple, Thierry ;
Mortier, Laurent ;
Moschos, Stergios J. ;
Hogg, David ;
Marquez-Rodas, Ivan ;
Del Vecchio, Michele ;
Lebbe, Celeste ;
Meyer, Nicolas ;
Zhang, Ying ;
Huang, Yingjie ;
Mookerjee, Bijoyesh ;
Long, Georgina V. .
LANCET ONCOLOGY, 2017, 18 (07) :863-873
[13]   Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma [J].
Diem, S. ;
Kasenda, B. ;
Spain, L. ;
Martin-Liberal, J. ;
Marconcini, R. ;
Gore, M. ;
Larkin, J. .
BRITISH JOURNAL OF CANCER, 2016, 114 (03) :256-261
[14]   Addition of an Iliac/Obturator Lymph Node Dissection Does Not Improve Nodal Recurrence or Survival in Melanoma [J].
Egger, Michael E. ;
Brown, Russell E. ;
Roach, Brent A. ;
Quillo, Amy R. ;
Martin, Robert C. G., II ;
Scoggins, Charles R. ;
Stromberg, Arnold J. ;
McMasters, Kelly M. .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2014, 219 (01) :101-108
[15]   Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy [J].
Eggermont, A. M. M. ;
Chiarion-Sileni, V. ;
Grob, J. -J. ;
Dummer, R. ;
Wolchok, J. D. ;
Schmidt, H. ;
Hamid, O. ;
Robert, C. ;
Ascierto, P. A. ;
Richards, J. M. ;
Lebbe, C. ;
Ferraresi, V. ;
Smylie, M. ;
Weber, J. S. ;
Maio, M. ;
Bastholt, L. ;
Mortier, L. ;
Thomas, L. ;
Tahir, S. ;
Hauschild, A. ;
Hassel, J. C. ;
Hodi, F. S. ;
Taitt, C. ;
de Pril, V. ;
de Schaetzen, G. ;
Suciu, S. ;
Testori, A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1845-1855
[16]   Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial [J].
Eggermont, Alexander M. M. ;
Suciu, Stefan ;
Santinami, Mario ;
Testori, Alessandro ;
Kruit, Wim H. J. ;
Marsden, Jeremy ;
Punt, Cornelis J. A. ;
Sales, Francois ;
Gore, Martin ;
MacKie, Rona ;
Kusic, Zvonko ;
Dummer, Reinhard ;
Hauschild, Axel ;
Musat, Elena ;
Spatz, Alain ;
Keilholz, Ulrich .
LANCET, 2008, 372 (9633) :117-126
[17]   Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma [J].
Eggermont, Alexander M. M. ;
Blank, Christian U. ;
Mandala, Mario ;
Long, Georgina, V ;
Atkinson, Victoria ;
Dalle, Stephane ;
Haydon, Andrew ;
Lichinitser, Mikhail ;
Khattak, Adnan ;
Carlino, Matteo S. ;
Sandhu, Shahneen ;
Larkin, James ;
Puig, Susana ;
Ascierto, Paolo A. ;
Rutkowski, Piotr ;
Schadendorf, Dirk ;
Koornstra, Rutger ;
Hernandez-Aya, Leonel ;
Maio, Michele ;
van den Eertwegh, Alfonsus J. M. ;
Grob, Jean-Jacques ;
Gutzmer, Ralf ;
Jamal, Rahima ;
Lorigan, Paul ;
Ibrahim, Nageatte ;
Marreaud, Sandrine ;
van Akkooi, Alexander C. J. ;
Suciu, Stefan ;
Robert, Caroline .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (19) :1789-1801
[18]   Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial [J].
Eggermont, Alexander M. M. ;
Chiarion-Sileni, Vanna ;
Grob, Jean-Jacques ;
Dummer, Reinhard ;
Wolchok, Jedd D. ;
Schmidt, Henrik ;
Hamid, Omid ;
Robert, Caroline ;
Ascierto, Paolo A. ;
Richards, Jon M. ;
Lebbe, Celeste ;
Ferraresi, Virginia ;
Smylie, Michael ;
Weber, Jeffrey S. ;
Maio, Michele ;
Konto, Cyril ;
Hoos, Axel ;
de Pril, Veerle ;
Gurunath, Ravichandra Karra ;
de Schaetzen, Gaetan ;
Suciu, Stefan ;
Testori, Alessandro .
LANCET ONCOLOGY, 2015, 16 (05) :522-530
[19]   Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma [J].
Eggermont, Alexander M. M. ;
Suciu, Stefan ;
Testori, Alessandro ;
Santinami, Mario ;
Kruit, Wim H. J. ;
Marsden, Jeremy ;
Punt, Cornelis J. A. ;
Sales, Francois ;
Dummer, Reinhard ;
Robert, Caroline ;
Schadendorf, Dirk ;
Patel, Poulam M. ;
de Schaetzen, Gaetan ;
Spatz, Alan ;
Keilholz, Ulrich .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (31) :3810-3818
[20]   Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma [J].
Faries, M. B. ;
Thompson, J. F. ;
Cochran, A. J. ;
Andtbacka, R. H. ;
Mozzillo, N. ;
Zager, J. S. ;
Jahkola, T. ;
Bowles, T. L. ;
Testori, A. ;
Beitsch, P. D. ;
Hoekstra, H. J. ;
Moncrieff, M. ;
Ingvar, C. ;
Wouters, M. W. J. M. ;
Sabel, M. S. ;
Levine, E. A. ;
Agnese, D. ;
Henderson, M. ;
Dummer, R. ;
Rossi, C. R. ;
Neves, R. I. ;
Trocha, S. D. ;
Wright, F. ;
Byrd, D. R. ;
Matter, M. ;
Hsueh, E. ;
MacKenzie-Ross, A. ;
Johnson, D. B. ;
Terheyden, P. ;
Berger, A. C. ;
Huston, T. L. ;
Wayne, J. D. ;
Smithers, B. M. ;
Neuman, H. B. ;
Schneebaum, S. ;
Gershenwald, J. E. ;
Ariyan, C. E. ;
Desai, D. C. ;
Jacobs, L. ;
McMasters, K. M. ;
Gesierich, A. ;
Hersey, P. ;
Bines, S. D. ;
Kane, J. M. ;
Barth, R. J. ;
McKinnon, G. ;
Farma, J. M. ;
Schultz, E. ;
Vidal-Sicart, S. ;
Hoefer, R. A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (23) :2211-2222